Acticor Biotech SAS Future Growth
Future criteria checks 4/6
Acticor Biotech SAS is forecast to grow earnings at 81.5% per annum. EPS is expected to grow by 85.2% per annum.
Key information
81.5%
Earnings growth rate
85.2%
EPS growth rate
| Biotechs earnings growth | 27.1% |
| Revenue growth rate | n/a |
| Future return on equity | 415.9% |
| Analyst coverage | Low |
| Last updated | 25 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | N/A | 16 | 17 | 17 | 1 |
| 12/31/2024 | N/A | -13 | -13 | -13 | 1 |
| 12/31/2023 | N/A | -15 | -15 | -15 | 1 |
| 6/30/2023 | N/A | -19 | -14 | -14 | N/A |
| 3/31/2023 | N/A | -17 | -13 | -13 | N/A |
| 12/31/2022 | N/A | -16 | -12 | -12 | N/A |
| 9/30/2022 | N/A | -15 | -13 | -13 | N/A |
| 6/30/2022 | N/A | -14 | -14 | -14 | N/A |
| 3/31/2022 | N/A | -13 | -14 | -14 | N/A |
| 12/31/2021 | N/A | -13 | -14 | -14 | N/A |
| 9/30/2021 | N/A | -11 | -12 | -12 | N/A |
| 6/30/2021 | N/A | -10 | -10 | -10 | N/A |
| 3/31/2021 | N/A | -9 | -8 | -8 | N/A |
| 12/31/2020 | N/A | -8 | -7 | -7 | N/A |
| 12/31/2019 | N/A | -5 | -4 | -4 | N/A |
| 12/31/2018 | 0 | -6 | -6 | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALACT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.1%).
Earnings vs Market: ALACT is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ALACT is expected to become profitable in the next 3 years.
Revenue vs Market: Insufficient data to determine if ALACT's revenue is forecast to grow faster than the French market.
High Growth Revenue: ALACT is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ALACT's Return on Equity is forecast to be very high in 3 years time (415.9%).